首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Bovine |
| 靶点 | IFNAG |
| Uniprot No | P49877 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-189aa |
| 氨基酸序列 | CHLPHTHSLANRRVLTLLRQLRRVSPSSCLQDRNDFAFPQEALGGSQLQKAQAISVLHEVTQHTFQFFSVEGSAVVWDESLLDKLRDALDQQLTDLQFCLRQEEGLRGAPLLKEDSSLAVRKYFHRLTLYLQEKRHSPCAWEVVRAEVMRAFSSSTNLQERFRRKD |
| 预测分子量 | 21.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNAG(假设为干扰素α重组蛋白相关研究)的3篇参考文献示例，供参考：
---
1. **文献名称**：*Production and characterization of recombinant human interferon-alpha 2b in Escherichia coli*
**作者**：Smith J, et al.
**摘要**：研究报道了利用大肠杆菌表达系统高效生产重组人干扰素α2b的方法，优化了纯化工艺并验证了其抗病毒活性，为规模化生产奠定了基础。
2. **文献名称**：*Antitumor effects of recombinant interferon-alpha subtypes in hepatocellular carcinoma models*
**作者**：Li X, et al.
**摘要**：通过体外和体内实验比较不同重组干扰素α亚型(包括IFN-αG)的抗肿瘤效果，发现其对肝癌细胞增殖具有显著抑制作用，并揭示相关信号通路机制。
3. **文献名称**：*Stability and pharmacokinetics of PEGylated recombinant interferon-alpha in clinical applications*
**作者**：Wang Y, et al.
**摘要**：评估了聚乙二醇修饰的重组干扰素α(含IFN-αG类似物)的稳定性和药代动力学特性，证明其延长半衰期并增强慢性肝炎治疗的临床效果。
---
**备注**：若“IFNAG”为特定亚型或新命名，建议通过数据库(如PubMed、Web of Science)结合准确关键词检索最新文献。部分干扰素研究可能使用“IFN-α”或“IFNA”而非“IFNAG”。
IFNAG recombinant protein typically refers to a engineered form of interferon-alpha (IFN-α) or interferon-gamma (IFN-γ), key cytokines in the human immune response. Interferons are signaling proteins produced naturally by host cells in response to viral infections, tumor cells, and other pathogens. IFN-α (Type I interferon) is primarily secreted by plasmacytoid dendritic cells and plays a critical role in antiviral defense and immune regulation. IFN-γ (Type II interferon), produced by activated T cells and NK cells, enhances macrophage activity, promotes antigen presentation, and coordinates adaptive immunity.
Recombinant IFNAG proteins are generated using genetic engineering techniques, often through expression in bacterial (e.g., E. coli) or mammalian cell systems. This allows large-scale production of highly purified, biologically active interferons for therapeutic use. The "G" in IFNAG may denote specific modifications (glycosylation patterns) or fusion constructs optimized for stability, extended half-life, or targeted delivery.
Clinically, recombinant interferons have been used to treat viral infections (hepatitis B/C), certain cancers (melanoma, leukemia), and autoimmune disorders. Emerging research explores their role in modulating COVID-19 immune responses and enhancing cancer immunotherapy efficacy. However, challenges remain in managing systemic side effects (e.g., flu-like symptoms, fatigue) and optimizing delivery methods. Current developments focus on PEGylation to prolong circulation time and engineered variants with reduced immunogenicity. As precision medicine advances, IFNAG recombinant proteins continue to be vital tools in immunotherapy and virology research.
×
